INTERNATIONAL LIVER CANCER ASSOCIATION

International Liver Cancer Association 16th Annual Conference

 

1-4 September 2022 , Madrid, Spain
Close
N. Poster
Poster title
Applicant name
Status
  P-01 Deciphering the epigenetic dependencies of intrahepatic cholangiocarcinoma Juan Lafuente-Barquero Received Received
  P-03 Metabolic characterization of non-alcoholic fatty liver disease-related hepatocellular carcinoma Monika Lewinska Received Received
  P-05 Multidimensional analyses reveal immunosuppressive microenvironment of hepatitis B virus-related hepatocellular carcinoma Yunhua Lee Received Received
  P-06 Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic-cholangiocarcinoma. margherita rimini Received Received
  P-08 Identifying regulatory transcription factors in primary liver cancer cell lineage commitment using single cell ATAC sequencing Amanda Craig Received Received
  P-11 A small hairpin of long noncoding RNA NIHCOLE promotes DNA double-strand break synapsis and ligation in hepatocellular carcinoma Puri Fortes Received Received
  P-12 Association of RNA sequencingbased gene signatures and clinical outcomes of lenvatinib (len) pembrolizumab (pembro) in hepatocellular carcinoma (HCC): results from study 116/KEYNOTE-524 Richard S. Finn Received Received
  P-13 Regulatory diversity of cancer stem cell marker expressions underscores intertumoral heterogeneity with therapeutic implication in hepatocellular carcinoma Yu Man Tsui Received Received
  P-14 Distinct lymphoid cell populations in intrahepatic cholangiocarcinoma and hepatocellular carcinoma Emily Kawaler Received Received
  P-15 Patient-derived organoids as new in vitro model for the study of hepatoblastoma Laura Zanatto Received Received
  P-16 Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutated clusters Margherita Rimini Received Received
  P-19 PLATELET C3G REGULATES HEPATOCARCINOMA PROGRESSION. Cristina Baquero Received Received
  P-20 Utilizing MALDI imaging mass spectrometry to analyze N-glycosylation of patient-matched serum and tissue hepatocellular carcinoma Andrew DelaCourt Received Received
  P-21 Dissecting the direct immunomodulatory potential of VEGF and PD-1 blockade in blood and tissue Gloryanne Aidoo-Micah Received Received
  P-22 Kruppel-Like Factor 10 Deletion and Hepatocellular Carcinoma Development Sung Hwan Yoo Received Received
  P-23 Evaluation of Stage Migration as a Predictor of Overall Survival in Patients with Hepatocellular Carcinoma Treated with Transarterial Chemoembolization. A Multi-center Study Neehar Parikh Received Received
  P-24 The tumor suppressor roles of miR-3185 in Hepatocellular Carcinoma Inah Marie Aquino Received Received
  P-25 Dual role of TGF- signatures in human B viral multistep hepatocarcinogenesis: early and late responsive genes Young Nyun Park Received Received
  P-26 IDH1 IN INTRAHEPATIC CHOLANGIOCARCINOMA: A COMPARATIVE GENOMIC ANALYSIS AND CLINICAL IMPACT. margherita rimini Received Received
  P-27 Evaluating the roles of DNA-PK in hepatocellular carcinoma Fanni Palinkas Received Received
  P-28 Preclinical proof-of-concept testing for potential synthetic lethality targeting homologous recombination-deficient hepatocellular carcinomas Jihyun An Received Received
  P-29 The heterogeneity of Perivenous-type (CTNNB1-mutated) hepatocellular carcinomas involves inflammatory escape and STEM-cell features Desquilles Lise Received Received
  P-30 Differential association of single nucleotide polymorphisms related to hepatocellular carcinoma in Hispanics and Caucasians Andre Boonstra Received Received
  P-31 Analysis of distinct tumor associated macrophage (TAM) phenotypes and myeloid subsets in human intrahepatic cholangiocarcinoma (iCCA) compared to hepatocellular carcinoma (HCC) by single cell sequencing Daniel Weissinger Received Received
  P-32 In vitro treatment of hepatocellular carcinoma organoids reveals additive rather than synergistic effects of doxorubicin and hypoxia Lauriane Blukacz Received Received
  P-33 AURORA KINASE A IN HCC: A POSSIBLE ROLE IN PD-L1 REGULATION Luca Grisetti Received Received
  P-34 HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis Amit Singal Received Received
  P-35 Racial, Ethnic, and Socioeconomic Disparities in Treatment Delay among Patients with Hepatocellular Carcinoma in the United States Amit Singal Received Received
  P-36 The importance of metabolic syndrome status for the risk of non-viral hepatocellular carcinoma: a nationwide study Yuri Cho Received Received
  P-37 A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance Ahlim Lee Received Received
  P-38 Healthcare costs and expenditures for Patients with Hepatocellular Carcinoma in the United States Amit Singal Received Received
  P-39 Myosteatosis and visceral adiposity may be novel predictors for mortality in patients with hepatocellular carcinoma treated with sorafenib Minkyu Kang Received Received
  P-40 Macrotrabecular-Massive histologic subtype is associated with ahigher riskof the recurrence of hepatoecelluar carcinoma Sung Hwan Yoo Received Received
  P-42 Assessment of the compliance and influencing factors of liver cancer screening in a high-risk population: A cross-sectional study Maomao Cao Received Received
  P-44 Predicting metabolic liver-specific fingerprint in Hepatocellular Carcinoma using a novel bioinformatics pipeline Sergio Barace Received Received
  P-45 Viral Hepatitis Status is Not Associated with Increased Odds of Complications Compared to Non-Viral Hepatitis After Liver Resection for Hepatocellular Carcinoma: A National Surgical Quality Improvement Program Analysis Luckshi Rajendran Received Received
  P-47 LI-RADS Category on MRI Predicts Recurrence of Intrahepatic Cholangiocarcinoma After Surgery: A Multicenter Study Sunyoung Lee Received Received
  P-48 Prevalence and pattern of alcohol consumption in patients with hepatocellular carcinoma. María Varela Calvo Received Received
  P-49 Compliance of the screening for hepatocellular carcinoma in patients with chronic hepatitis B or C Won Sohn Received Received
  P-52 Does HCC surveillance improve survival rate? A retrospective comparative study between patients diagnosed within and outside surveillance over a 10 year period A single centre study Swetha Palanichamy Received Received
  P-53 Characteristics and survival of patients with hepatocellular carcinoma in natural history in a western country. Maria Sánchez Received Received
  P-54 Epidemiology, real-world treatment patterns and clinical outcomes of systemic treatments in unresectable hepatocellular carcinoma: a systematic review Cal Shephard Received Received
  P-58 A machine learning model for predicting hepatocellular carcinoma risk in patients with chronic hepatitis B Hye Won Lee Received Received
  P-59 Urinary Microbiome-Based Metagenomic Signature for Non-invasive Diagnosis of Hepatocellular Carcinoma Eun Ju Cho Received Received
  P-61 Estimating postsurgical outcomes of patients with a single hepatocellular carcinoma using gadoxetic acid-enhanced MRI: Risk scoring system development and validation Bohyun Kim Received Received
  P-63 Protein biomarkers in HCC Robin Zenlander Received Received
  P-65 Accurate diagnosis of HCC in cirrhotic patients with a novel protease assay compared to standard AFP Tram Tran Received Received
  P-67 Noninvasive prediction of hepatocellular carcinoma development after oral antiviral therapy in patients with chronic hepatitis C: A multicenter study Yu Rim Lee Received Received
  P-68 Differentiation hepatic angiomyolipoma and hepatocellular carcinoma in patients without risk of hepatocellular carcinoma Hyungjin Rhee Received Received
  P-69 Early Detection of Hepatocellular Carcinoma via methylation-sensitive high-resolution melting-based Liquid Biopsy Su Jong Yu Received Received
  P-70 Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy Jae Seung Lee Received Received
  P-72 Hepatocellular carcinoma with fatty change: association of underlying liver disease and clinicopathologic characteristics Jae Hyon Park Received Received
  P-74 FROM TISSUE TO SERUM- SPATIAL OMICS USED TO DEVELOP A NOVEL BIOMARKER FOR CHOLANGIOCARCINOMA Shaaron Ochoa Rios Received Received
  P-75 Association between intensity of imaging surveillance and clinical outcomes in patients with hepatocellular carcinoma Jeong Ah Hwang Received Received
  P-77 Low risk of seeding following percutaneous needle biopsy of intrahepatic cholangiocarcinoma (iCCA) Gianluca Fornoni Received Received
  P-78 Optimal imaging criteria and modality to determine Milan criteria for prediction of post-transplant HCC recurrence after locoregional treatment Mi-Suk Park Received Received
  P-80 Circulating cytokines reflective of the etiology-specific immune environment in cirrhosis and HCC Andre Boonstra Received Received
  P-81 Albumin RNA in situ hybridization and filamin A are helpful for differentiation of small duct type intrahepatic cholangiocarcinoma from extrahepatic adenocarcinomas Young Nyun Park Received Received
  P-82 Impact of the COVID-19 pandemic in the diagnosis and therapy of single hepatocellular carcinoma less than 3 cm in a western country. Maria Valera Received Received
  P-83 Plasma cytokine levels and circulating DNA in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma Elena Vargas-Accarino Received Received
  P-86 Diagnostic Performance of LI-RADS v2018 Versus KLCA-NCC 2018 Criteria for Hepatocellular Carcinoma Using MRI: A Meta-Analysis of Comparative Studies Sunyoung Lee Received Received
  P-87 Investigating historic aMAP scores in a population of NAFLD/NASH related Hepatocellular Carcinoma patients and studying variations in scores between cirrhotic and non-cirrhotic groups Avisnata Das Received Received
  P-89 Screening with a reduction of liver cancer mortality: a systematic review and meta-analysis Maomao Cao Received Received
  P-93 EURopean Field of Practice Study of Atezolizumab and Bevacizumab in HepatoCellular Carcinoma (EURAB-HCC) Gloryanne Aidoo-Micah Received Received
  P-94 Treatment-related adverse events and improved survival in pts treated with atezolizumab plus bevacizumab: a global, real-world study. Antonio DAlessio Received Received
  P-97 Previous variceal bleeding is associated with variceal bleeding under atezolizumab-Bevacizumab treatment Manon Allaire Received Received
  P-99 Regorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in routine clinical practice: Final analysis of the prospective, observational REFINE study kirhan ozgurdal Received Received
  P-100 RAdiation SEgmentectomy for cuRative intent of unresectable very early to early stage hepatocellular carcinoma (RASER): A prospective, single-centre, single-arm study Alex Sher Received Received
  P-101 Trial in progress: Atezolizumab and Bevacizumab Pre-Liver Transplantation for Patients with Hepatocellular Carcinoma Beyond Milan Criteria Gonzalo Sapisochin Received Received
  P-102 Early Nivolumab addition to Regorafenib in patients with hepatocellular carcinoma progressing under first line therapy (GOING trial). Interim analysis and safety profile Marco Sanduzzi Zamparelli Received Received
  P-103 A network meta-analysis of non-surgical locoregional therapies in patients with early hepatocellular carcinoma Jihyun An Received Received
  P-105 Semaglutide prevents the progression of hepatocellular carcinoma in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH Michael Feigh Received Received
  P-106 REACH-2 and REACH: Exploratory efficacy and safety results in Chinese hepatocellular carcinoma (HCC) patients with extrahepatic spread (EHS) Junjun Liu Received Received
  P-108 Impact of dose adjustment on clinical outcome of lenvatinib-treated patients with advanced hepatocellular carcinoma (HCC) Stephen Lam Chan Received Received
  P-109 Marked Interdisciplinary Differences in Treatment Strategies Exist in the Management of Combined Hepatocellular-cholangiocarcinoma Patients: An International Multicenter Evaluation of Hospital-wide Treatment Strategies Marco Claasen Received Received
  P-111 A five year experience of assessing patients for liver transplantation in HCC: acceptance rates and outcomes. Rosemary Faulkes Received Received
  P-113 R1 VASCULAR OR PARENCHYMAL MARGINS: WHAT IMPACT AFTER RESECTION OF INTRAHEPATIC CHOLANGIOCARCINOMA? Mabilia Andrea Received Received
  P-114 Early variation of serum AFP predicts outcomes under atezolizumab/bevacizumab for advanced hepatocellular carcinoma Claudia Campani Received Received
  P-115 Spontaneously ruptured hepatocellular carcinoma on non-cirrhotic liver: treatment and prognosis. Marta Romero-Gutiérrez Received Received
  P-116 The cumulative incidence of hepatocellular carcinoma according to care cascade in patients with anti-HCV positive HYUN WOONG LEE Received Received
  P-117 Renal disfunction in patients treated with atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma Hitomi Takada Received Received
  P-121 PRIMER-1: A randomised phase II trial of Perioperative pembrolizumab and lenvatinib in resectable Hepatocellular Carcinoma (HCC) Tim Meyer Received Received
  P-122 Perioperative Therapy with Durvalumab Plus Tremelimumab for Patients with Resectable Hepatocellular Carcinoma - A Phase II Trial (NEOTOMA) OKane Grainne Received Received
  P-123 Surveillance in Liver Cancer The SILVER study Rohini Sharma Received Received
  P-124 Open label, randomised, phase 2 study to evaluate the safety and efficacy of sorafenib with or without MTL-CEBPA, an immune-modulatory saRNA upregulating C/EBP-a, as second line treatment in advanced hepatocellular carcinoma (OUTREACH 2) Nagy Habib Received Received
  P-125 Multiple arterial-phase of gadoxetic acid-enhanced MRI improves diagnosis of hepatocellular Carcinoma: Multicenter propensity score-matched analysis Sang Hyun Choi Received Received
  P-126 Clinical efficacy of stereotactic ablative body radiotherapy for oligometastatic hepatocellular carcinoma: a multi-institutional retrospective study (KROG 20-04) Tae Hyung Kim Received Received
  P-128 CT Radiomic Features of Colorectal Cancer Liver Metastasis for Predicting Upcoming Disease Progression After Initial Systemic Chemotherapy Joon-IL Choi Received Received
  P-129 TERT promoter mutations identified by ddPCR on FFPE samples: a surrogate marker of entry into liver carcinogenesis Aurelie Beaufrere Received Received
  P-135 An assessment of ed microRNAs in patients with hepatitis B, hepatitis C and with hepatocellular carcinoma Janusz Szemraj Received Received
  P-136 Interleukin-15 co-expression induces robust in vivo expansion and antitumor effect of Glypican-3-specific CAR T cells in a patient with liver cancer Tannaz Armaghany Received Received
  P-137 Transcriptome profiling of the intermediate cell carcinoma of the primary liver cancer Byungchan Jang Received Received
  P-138 Single-cell derived gene signatures identify responders to checkpoint inhibition in bulk transcriptome from advanced hepatocellular carcinoma Sarah Cappuyns Received Received
  P-139 Fast Deep learning quantification of tumor infiltrating lymphocytes with minimal training dataset Grousset Ruben Received Received
  P-140 MALDI imaging: a powerful tool to decipher intra-tumoral heterogeneity: combined hepato-cholangiocarcinomas as proof of concept Elia Gigante Received Received
  P-141 An image-based machine learning pipeline for the prediction of liver resection complexity from preoperative CT scans Omar Ali Received Received
  P-142 External Validation of the FSAC Model Using On-Therapy Response of Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B; a multicenter study Jae Seung Lee Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Cristina Miralles
Hours: Mon-Fri 8:30-15:00
18:36
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

International Liver Cancer Association 16th Annual Conference

 

1-4 September 2022 , Madrid, Spain
FAQs


Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 05/09/2022 TO 05/09/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert